GILD.NEO Gilead Sciences CDR (CAD Hedged)

Healthcare Drug Manufacturers - General NEO Exchange
34.54 CAD
Close of Oct 30, 2026
23.81 34.54
Market cap
CAD 280B
P/E
25.5x
P/B
16.28x
ROE
-143.3%
Dividend yield
1.88%
Fundamental score
1.4/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GILD.NEO undervalued?

Graham number

The Graham number of Gilead Sciences CDR (CAD Hedged) cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gilead Sciences CDR (CAD Hedged) fundamental analysis

7 of 21 checks passed

ROE 0/2

Low return on equity (-143.3%), below 10%.

ROA 0/1

Return on assets (-34.3%) is below the industry median (7.4%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (1,680.9%) is above the industry median (90.5%).

Revenue Growth 1/2

Revenue grew 2.6% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (201.5%), above 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Cash Runway 2/2

Loss-making but free cash flow is positive.

PE vs Market 0/1

PE (25.0x) is above the market median (20.3x).

PE vs Industry 0/1

PE (25.0x) is above the industry median (25.0x).

PBV 0/1

Price to book (16.0x) is above the industry median (8.1x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 399.8, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (1.9%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 47.0%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Gilead Sciences CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gilead Sciences CDR (CAD Hedged)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatmen…

Full company profile